Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma
Conditions: Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse Intervention: Drug: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy Sponsors: Second Affiliated Hospital of Xi'an Jiaotong University; Nanjing Legend Biotech Co. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials